EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data

Norbert Marschner, Wolfgang Knauf

Oncology Research and Treatment · 2024

DOI: 10.1159/000536652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research and Treatment, 2024. Verfasst von Norbert Marschner und 1 weiteren Autor:innen. Beteiligte Einrichtung: Klinisches Forschungsinstitut iOMEDICO, Freiburg, Germany. Hauptthemen laut MEDLINE: Neoplasms, Ambulatory Care, Medical Oncology. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Survival data reported by randomised controlled trials are collected in a highly selected patient population and can thus only be transferred to a limited extent to real-world patients: the patients in routine care are mostly older, present with more comorbidities and a worse general state of health. This so-called efficacy-effectiveness gap typically results in inferior survival data in routine healthcare.

Methods

Six prospective clinical tumour registries recruited a total of 11,679 patients receiving systemic therapy in haemato-oncological practices in Germany between 2006 and 2020. For these patients with advanced colorectal cancer, breast cancer, lung cancer, pancreatic cancer, renal cell cancer, and lymphatic neoplasms, overall survival was analysed. A comprehensive literature search was performed to identify suitable pivotal randomised controlled trials.

Results

Median overall survival of patients treated in German routine care, with advanced colorectal, breast, lung, and pancreatic cancer, as well as with diffuse large B‐cell lymphoma and multiple myeloma, is not shorter than the respective survival data reported in trials. Patients with advanced renal cell carcinoma, chronic lymphocytic leukaemia, or indolent non-Hodgkin lymphoma showed slightly lower survival rates compared to clinical trials.

Conclusions

Despite less favourable patient characteristics, survival data from patients with cancer treated in ambulatory routine care in Germany are in range with results from randomised controlled studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAmbulatory CareMedical OncologyHumansGermanyFemaleMaleAgedMiddle AgedRegistriesSurvival RateProspective StudiesAged, 80 and overRandomized Controlled Trials as TopicAdult

Stichwörter der Autor:innen

Cancer registriesCohort studyOncologyOutpatient careOverall survivalReal-world data

Autor:innen und Institutionen

  • Klinisches Forschungsinstitut iOMEDICO, Freiburg, Germany.
  • Medizinische Klinik I, Universitätsklinikum Freiburg, Freiburg, Germany.
  • Berufsverband der Niedergelassenen Ärztinnen und Ärzte für Hämatologie und Medizinische Onkologie in Deutschland e.V. (BNHO e.V.), Cologne, Germany.
  • Centrum für Hämatologie und Onkologie Bethanien, Frankfurt am Main, Germany.

Zitieren

APA

Marschner, N., & Knauf, W. (2024). Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data. Oncology Research and Treatment. https://doi.org/10.1159/000536652

Vancouver

Marschner N, Knauf W. Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data. Oncology Research and Treatment. 2024. doi:10.1159/000536652

BibTeX
@article{Marschner2024,
  author = {Marschner, Norbert and Knauf, Wolfgang},
  title = {Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data},
  journal = {Oncology Research and Treatment},
  year = {2024},
  doi = {10.1159/000536652}
}
Kostenlos starten →